002432 九安医疗
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,069,312-48.89%2,592,1963,231,12526,315,3612,397,098
减:营业总成本1,275,596-9.60%1,884,2142,186,3117,434,7301,447,684
    其中:营业成本369,996-37.55%760,1981,176,5725,367,195875,549
               财务费用(7,916)-183.21%(6,631)(199,522)(209,149)2,602
               资产减值损失(13,872)59.04%(53,479)(309,867)(321,559)(9,274)
公允价值变动收益1,251,365110.86%739,622309,288(326,401)30,489
投资收益562,4733.61%712,471560,73893,48345,583
    其中:对联营企业和合营企业的投资收益--------(1,266)(1,380)
营业利润1,595,069-12.24%2,109,8021,613,49118,311,8691,002,549
利润总额1,596,307-12.15%2,106,8701,580,34418,257,857999,632
减:所得税费用8,549-96.99%306,828231,1121,773,76365,229
净利润1,587,7583.53%1,800,0421,349,23216,484,094934,403
减:非控股权益(1,306)-100.79%131,31597,624453,92525,761
股东净利润1,589,06516.11%1,668,7271,251,60816,030,169908,642

市场价值指针
每股收益 (元) *3.65614.74%3.8142.81535.1381.999
每股派息 (元) *----0.2000.3002.5000.700
每股净资产 (元) *47.73021.43%42.07939.38140.3575.967
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容